Articles tagged with Positron Emission Tomography
Researchers found that ketamine increases serotoninergic neurons in brain areas regulating motivation, suggesting its antidepressant action. The PET imaging studies demonstrate the potential of the technology in diagnosing major depressive disorder and developing new antidepressants.
Researchers used 18F-FDOPA PET imaging to differentiate between radiation-induced lesions and new tumor growth in brain metastases patients, achieving an accuracy of 83% with visual scoring. The study found that 18F-FDOPA PET imaging was highly prognostic of progression-free survival and overall survival.
A study found increased deposits of β-Amyloid (Aβ) plaques in some areas of the brains of patients with traumatic brain injury (TBI). Researchers discovered Aβ plaque increases may be linked to TBI and accelerated Alzheimer's Disease progression.
Researchers from Uppsala University use PET scanning to visualize elevated levels of NK1 receptors in painful tissue, shedding light on the underlying mechanisms of chronic tennis elbow. The study provides a promising diagnostic method for localizing and diagnosing soft tissue pain.
PET scans can identify patients with more aggressive tumors, enabling intensified treatment for locally advanced lung cancer. The study found a strong correlation between radiation dose intensity and local control of the cancer.
Researchers found that patients diagnosed with early Alzheimer's disease who received brain imaging test results had better clinical outcomes, including superior executive function and memory abilities. The study suggests that earlier diagnosis can lead to significant benefits, potentially saving healthcare dollars.
Researchers have developed a novel molecular probe detectable by PET imaging, providing the first non-invasive visualization of myelin integrity in the entire spinal cord. The discovery brings new hope for accurate diagnosis and prognosis, allowing clinicians to monitor disease progression and evaluate therapy efficacy.
Researchers developed a new class of imaging agents to visualize tau protein aggregates, a hallmark of Alzheimer's disease. The use of these fluorescent compounds in PET tests provides valuable information on brain regions at risk for tau-induced neuronal death.
Researchers used PET scans to identify hypermetabolism in the spine, indicating a potentially reversible phase of degenerative cervical myelopathy. Patients with this marker showed significant improvement after decompressive surgery, while those without exhibited no change.
Researchers used PET scanning to map changes in brain metabolism in Huntington's disease gene carriers, identifying a characteristic network of abnormalities. This finding enables the tracking of disease progression and will aid in evaluating the effects of new drugs before symptoms appear.
Researchers at ETH Zurich developed a new PET tracer that targets the folic acid receptor on cancer cells, enabling precise diagnosis and predicting patient response to therapy. The tracer also has potential for displaying inflammatory diseases and medication development.
Researchers found that PET-CT improved staging accuracy and intrathoracic disease identification in limited-stage small-cell lung cancer patients. This led to an improvement in overall survival rates compared to those not staged with PET-CT.
A study found specific patterns of brain activity can indicate whether a patient will respond to medication or psychotherapy for depression. Low activity in the anterior insula region was associated with remission through CBT, while high activity was linked to improved response to medication.
Researchers have developed a new segmentation technique using automatic thresholding to improve PET image analysis for optimizing radiotherapy treatments. The technique has shown promising results and could be highly useful in clinical practice.
The new SPECT/MR system offers exceptional molecular imaging capabilities, reducing patient exposure to ionizing radiation and offering customized multifunctional imaging. It has the potential to diversify options for clinicians and biomedical investigators, with possible human trials in the near future.
A comparative heart imaging study found that PET/MR measures up to PET/CT in cardiac applications, with comparable results for heart muscle viability assessment. The technology has implications for future studies into ischemic cardiomyopathy and arrhythmia development after cardiac arrest.
The new technology uses tiny radiofrequency solenoids to track patient movement, optimizing image reconstruction and reducing artifacts. This innovation improves brain imaging for patients with dementia, leading to better diagnostic imaging and therapy monitoring.
Researchers found that metabolic PET imaging detected coronary disease at an early stage, with a sensitivity of 96%, compared to 56% for MPI. This technique could potentially be used for initial CAD screening to help doctors better determine a patient's cardiac risk and manage care.
Researchers used parallel PET/MR imaging to map chemotherapy distribution before surgery, improving risk stratification and patient management. This study suggests simultaneous PET/MR imaging can benefit patients by predicting cancer recurrence and avoiding unnecessary chemotherapy.
A new molecular imaging technique, F-18 FET, has been shown to be highly effective in detecting and differentiating brain lesions in children, with an accuracy rate of 94%. This study improves the clinical management of pediatric brain cancer patients by providing more accurate information about tumor progression and treatment.
Researchers found hypometabolism in brain regions associated with Alzheimer's disease, even in cognitively normal subjects with amyloid plaque. This association suggests a potential early indicator of Alzheimer's disease before dementia sets in.
A new hybrid molecular imaging system combines positron emission tomography and magnetic resonance to detect recurrent prostate cancer. The study reveals that PET/MR finds more areas of metastases than PET/CT, making it a viable alternative for restaging patients with metastatic prostate cancer.
Noninvasive imaging tests like CT, MR, and PET may help evaluate and manage diabetes by assessing changes in fat composition and distribution. This can aid in early disease detection and identify functional abnormalities before symptoms appear.
Researchers at RIKEN have developed a new molecular imaging technology that visualizes both bio-metals and molecules simultaneously in a live mouse. This breakthrough technology is expected to provide insights into the complex interactions between metal elements and associated bio-molecules in diseases such as diabetes and cancer.
Researchers have identified nine biomarkers associated with the buildup of toxic protein amyloid beta in the brain, which occurs years before symptoms appear. The discovery has the potential to lead to the development of an early screening test for Alzheimer's disease, giving those at risk a better chance of receiving treatment earlier.
A new PET test using 11C-PIB offers a non-invasive method to visualize amyloid deposits in the heart, providing valuable information for disease prognosis and treatment monitoring. The study demonstrated positive uptake of 11C-PIB in patients with cardiac amyloidosis.
The Society of Nuclear Medicine and Molecular Imaging has published the first guidelines for brain amyloid imaging in Alzheimer's disease, providing a framework for healthcare practitioners to determine when to order this test. The guidelines emphasize that amyloid PET imaging should be used judiciously, particularly among elderly indi...
New research reveals that 18F-FDG PET/CT provides better prognostic information than conventional imaging, changing management for over 50% of patients. The study found that PET/CT accurately identified lesions in multiple areas, leading to revised staging and treatment plans.
Researchers at Duke University Medical Center found that combining diagnostic tests more accurately predicts Alzheimer's in patients with mild cognitive impairment. The combination of MRI, FDG-PET, and cerebrospinal fluid analysis reduced misdiagnoses by 28.4% compared to individual tests.
A combination of diagnostic tests, including MRI, PET and cerebrospinal fluid biomarkers, can improve the prediction of conversion from mild cognitive impairment to Alzheimer's disease. The study found that combining these tests reduced false classifications and increased accuracy compared to clinical testing alone.
Researchers used PET imaging to evaluate tumor grade and cellular proliferation in patients with gliomas. The study found that F-18-FLT PET provided a more comprehensive view of tumor grade and correlated with overall survival, making it a valuable tool for guiding treatment.
A study published in Alzheimer Disease & Associated Disorders found that a florbetapir PET scan can alter physicians' diagnostic thinking, guiding treatment and further testing for patients with cognitive impairment. The test showed amyloid deposits in 113 out of 229 patients, leading to changes in diagnosis and treatment plans.
Researchers have developed omni-tomography, a technology that integrates multiple imaging modalities to improve early disease screening, cancer staging, and therapeutic assessment. This approach enables precise reconstruction of small areas in the body using prior knowledge and common properties.
Recent studies claiming to use brain scans for autism diagnosis are flawed and unreliable. Researchers need to conduct large-scale multicenter studies to understand the biological basis of autism.
Researchers used PET scans to visualize the effect of caffeine on brain adenosine receptors for the first time. The study found that up to 50% of A1 adenosine receptors were occupied by caffeine in regular coffee drinkers, suggesting a potential link to neurodegenerative diseases.
A study by researchers at the University of Pittsburgh found that increasing Omega-3 fatty acid intake improves working memory performance in healthy young adults aged 18-25. The participants showed enhanced cognitive abilities despite already being at their peak cognitive function. The study suggests a potential mechanism for brain en...
The chemistry building at Brookhaven National Laboratory has been designated an Historic Chemical Landmark in recognition of the development of 18FDG, a radiotracer that revolutionized brain imaging and cancer diagnosis worldwide. Over 1.5 million 18FDG PET scans are performed annually.
Researchers have discovered a new PET imaging agent that can predict the early response to treatment for head and neck cancer patients. The agent, 3'-deoxy-3'F-18-fluorothymidine (18-F-FLT), showed high accuracy in detecting therapeutic responses and identifying patients needing close follow-up.
A study found that stage IV cancer patients on Medicare are more likely to undergo high-cost diagnostic imaging procedures, which may be driven by the increasing number of treatment options available. The use of imaging has steadily increased between 1995 and 2006, with costs rising faster than overall cancer care costs.
A new study has found that patients with mild or no cognitive impairment can be identified as at risk of developing Alzheimer's disease through a PET brain scan using a radioactive dye. The study, led by researchers at Duke University Medical Center, shows that the presence of amyloid plaques in the brain can predict future decline.
A new study published in Restorative Neurology and Neuroscience has shown that transcranial direct current stimulation (tDCS) can enhance the outcome of swallowing therapy for post-stroke dysphagia. tDCS improved post-stroke dysphagia in patients with long-lasting effects observed over three months.
Between 1996 and 2010, the use of advanced diagnostic imaging like CT and MRI tripled and nearly quadrupled, respectively. Estimated radiation exposure also increased substantially, with a significant association between CT usage and radiation dose.
A new vaccine against cocaine addiction uses the body's own immune system to prevent the high, as demonstrated by a molecular imaging technique. The vaccine, called dAd5GNE, combines a cocaine-like molecule with part of the common cold virus, inducing antibodies that bind cocaine in blood and prevent it from entering the brain.
A new study reveals that a combination of molecular imaging, radiography, and dual imaging probes detects more cancerous bone lesions than other methods. The addition of molecular imaging with combined radiopharmaceuticals to conventional CT improves the power of imaging for cancer diagnosis.
A new PET imaging technique using an amino acid probe can predict the effectiveness of brain cancer treatment as early as two weeks after initiation, without requiring invasive biopsies. This method provides vital information about the body's response to therapy and has shown promising results in patients with aggressive glioma tumors.
Researchers develop a molecular imaging tool to detect coronary artery disease, which is caused by atherosclerosis. The technique measures the coronary flow reserve, or CFR, and calculates precise dilation of blood vessels at rest and under stress.
A new method of 4D PET image reconstruction provides sharper-than-ever images of cardiac function, allowing physicians to pinpoint heart defects for better diagnoses. The technique compensates for blurring caused by the beating of the heart, improving imaging contrast and signal-to-noise ratio.
Research finds that combining molecular imaging with computed tomography (CT) can reduce patient radiation dose. By using just one CT scan for multiple PET studies, researchers lower radiation exposure and improve image quality.
A new molecular imaging method using PET/CT with Gallium-68 DOTATATE identifies hormonally active tissues, allowing clinicians to re-evaluate patient management. This technique changes treatment plans in over 35% of patients, saving them from unnecessary surgeries.
Researchers have made significant breakthroughs in Alzheimer's disease detection using molecular imaging technology, which can identify beta-amyloid plaques in the brain. Studies show that high levels of amyloid binding are associated with an 80% chance of developing Alzheimer's disease within two years.
Piramal Imaging will present data from five florbetaben studies, including a pivotal Phase III trial that will provide the basis for regulatory submission later this year. The company is developing an innovative and proprietary tracer portfolio to address major clinical needs in Alzheimer's disease and other conditions.
Researchers have identified a new way to predict the risk of sudden cardiac arrest by imaging nerve function in the heart. A study involving 204 patients with advanced heart disease found that those with at least 38% denervated myocardium were at highest risk of sudden cardiac arrest.
SPECT/CT scans have been shown to change clinical management in thyroid cancer patients by improving staging and risk stratification. The technology has been used both post-operatively and pre-ablation to identify metastatic lesions and adjust treatment approaches, leading to avoidance of unnecessary therapy.
A new human study suggests that dopamine levels in the brain play a crucial role in determining how hard people work. Individuals with higher dopamine activity in certain areas showed greater motivation and effort, while those with increased dopamine in other areas were less likely to exert effort.
A new method using florbetaben PET scans may help diagnose Alzheimer's disease earlier by detecting beta-amyloid plaques in the brain. The study found a sensitivity of 77% and specificity of 94% compared to post-mortem diagnosis, with even higher accuracy for visual assessments.
A study published in The Journal of Neuroscience found that primitive brain structures activate before neocortex when individuals regain consciousness after general anesthesia. This discovery provides new insights into the emergence of consciousness and its relationship with brain function.
A PET imaging agent has been shown to reverse neurotoxicity and improve motor skills and memory in animal models of Parkinson's disease. The compound works as a scavenger of peroxynitrite, reducing neuronal death and promoting revival of neuronal function.
A study by UCLA's Jonsson Comprehensive Cancer Center found that early Positron Emission Tomography (PET) response after neoadjuvant chemotherapy is associated with increased survival in patients with soft tissue sarcomas. Patients who showed a significant PET response had significantly longer survival rates compared to those who did not.
Photoacoustic tomography allows scientists to see deep beneath the skin with high contrast, revealing tissue oxygen use and cancer biomarkers. The technique enables non-invasive imaging for breast cancer staging, early chemotherapy response monitoring, melanoma detection, and gastrointestinal tract visualization.
Imaging amino acid transporters with PET/CT has significantly altered management plans for 41% of patients with brain tumors, according to research. The imaging modality has improved detection of primary and recurrent high- and low-grade brain tumors, leading to changes in treatment from 'watch and wait' to chemotherapy or vice versa.